Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (SNSE:BIIB) from Overweight to Neutral. There are 1,768 funds or institutions reporting positions in Biogen.

Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (BRSE:BIIB) from Overweight to Neutral. There are 1,768 funds or institutions reporting positions in Biogen.

Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (WBAG:BIIB) from Overweight to Neutral. There are 1,768 funds or institutions reporting positions in Biogen.

Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table summarizes their recent ratings, shedding light on ...

BIIB is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.31; value investors ...

Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new ...

Piper Sandler downgraded Biogen (BIIB) to Neutral from Overweight with a price target of $138, down from $315, following a transfer of coverage. Biogen remains in transition, as management ...

Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to ...

We recently compiled a list of the 12 Cheap Healthcare Stocks to Buy Heading into 2025. In this article, we are going to take ...

Biogen (BIIB) stock slipped as Piper Sandler downgraded the company to neutral from overweight, citing challenges in Alzheimer's drug market. Read more here.